Armgo
1 known investors
ARMGO develops a novel class of therapeutics called Rycals that target ryanodine receptors (RyRs) to correct calcium channel dysfunction in serious diseases with high unmet need. Its lead candidate, Surlorian, is being developed for heart failure by addressing an underlying driver of disease progression.
Investors · 1
In the news
Frequently asked questions
- What does Armgo do?
- ARMGO develops a novel class of therapeutics called Rycals that target ryanodine receptors (RyRs) to correct calcium channel dysfunction in serious diseases with high unmet need. Its lead candidate, Surlorian, is being developed for heart failure by addressing an underlying driver of disease progression.
- Who are Armgo's investors?
- Armgo's investors include Aisling Capital.